Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 7216 to 7230 of 7688 results

  1. Therapeutic hypothermia following cardiac arrest (IPG386)

    This guidance has been updated and replaced by NICE interventional procedures guidance 782.

  2. Chronic obstructive pulmonary disease: fluticasone furoate, umeclidinium and vilanterol (Trelegy) (ES18)

    This evidence summary has been updated and replaced by NICE guideline 115.

  3. Preventing recurrence of Clostridium difficile infection: bezlotoxumab (ES13)

    This advice has been updated and replaced by NICE guideline NG199.

  4. Nivolumab for adjuvant treatment of resected non-small-cell lung cancer [ID4053]

    In development [GID-TA10935] Expected publication date: TBC

  5. Sepsis (QS161)

    February 2024: We have temporarily withdrawn this quality standard due to ongoing updates to the NICE guideline on sepsis, which underpins the quality statements. See the guidance in development page and guideline in development page for progress on these updates.

    For any queries, please contact qualitystandards@nice.org.uk

  6. Imetelstat for treating relapsed or refractory transfusion-dependent myelodysplastic syndromes [ID3922]

    In development [GID-TA10800] Expected publication date: TBC

  7. High tibial osteotomy with adjustable magnetic nail insertion for symptomatic medial knee osteoarthritis

    Discontinued [GID-IPG10142]

  8. COVID-19 rapid guideline: severe asthma (NG166)

    May 2022: This guideline has been withdrawn because current practice is to manage COVID-19 risk in line with risk of other respiratory infections. See our guidance on treating severe asthma and our guideline on managing COVID-19.

  9. Palforzia for treating peanut allergy in children aged 1 to 3 [ID6144]

    In development [GID-TA11070] Expected publication date: TBC

  10. Health technology evaluations: interim methods and process guide for the proportionate approach to technology appraisals (PMG40)

    This interim methods and process guide for the proportionate approach to technology appraisals has been incorporated into NICE health technology evaluations: the manual.

  11. Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years (TA554)

    This guidance has been updated and replaced by NICE technology appraisal guidance 975.  

  12. Nivolumab with ipilimumab for untreated unresectable stage 3 non-small-cell lung cancer [ID6248]

    In development [GID-TA11253] Expected publication date: TBC

  13. Topical rapamycin for treating facial angiofibromas associated with tuberous sclerosis complex in people 6 years and over [ID6391]

    In development [GID-TA11455] Expected publication date: TBC